Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The addition of an inhaled long-acting beta-adrenergic agonist to an inhaled
glucocorticosteroid improves disease control in persistent asthma. This observation has
supported the use of long-acting beta-adrenergic agonist/glucocorticosteroid combination
preparations for the management of asthma. Currently, salmeterol/fluticasone and
formoterol/budesonide are available for clinical use. The long-term beneficial clinical
effects of the two drug classes seem to be synergistic, and several mechanisms of
glucocorticoid-beta-adrenergic agonist interactions involving gene transcription have been
invoked to explain this phenomenon.This study, wish to address the question whether
glucocorticoids can acutely potentiate the bronchodilator response to a long-acting
beta-adrenergic agonist.We expect that in patients with asthma, the short-term bronchodilator
effect of salmeterol is enhanced by the addition of fluticasone, which by itself has no
short-term bronchodilator effect. To test this premise, we will assess the respective
short-term effects of salmeterol (50 µg), fluticasone (250 µg), salmeterol/fluticasone
(50/250 µg), and placebo/placebo on spirometric parameters. Airway Blood flow will also be
measured to ensure that vasoconstriction does not occur.
Phase:
N/A
Details
Lead Sponsor:
University of Miami
Collaborator:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance